Study details
Enrolling now
Measuring Dupilumab's Effect on Lung Clearing
Sally E. Wenzel MD
NCT IDNCT04743791ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
30
Study length
about 4 years
Ages
18+
Locations
1 site in PA
About this study
This trial is testing if a drug called dupilumab helps improve lung clearing in adults with moderate to severe asthma. Participants will receive either dupilumab or a placebo for 1444 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Dupilumab
PhasePhase 4
DrugDupilumab
Primary goalChange in mucociliary clearance (MCC) rate
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
dupilumab
Endpoints
Primary: Change in mucociliary clearance (MCC) rate
Secondary: Change in FEV1% predicted
Body systems
Respiratory